D04 Biomarkers 1: Principles and Applicati<strong>on</strong>s Educati<strong>on</strong>al Objectives: 1. Highlight that biomarker performance is modified by c<strong>on</strong>text and cause 2. Discuss the use of phase specific biomarkers to triage to treatment Zoltan Endre MD, PhD 4:00-5:30 Tuesday, February 14 C<strong>on</strong>tent Descripti<strong>on</strong>: The EARLYARF trial was the first to utilize urinary biomarkers to triage patients to an interventi<strong>on</strong>. The interventi<strong>on</strong> (high dose erythropoietin) did not modify outcome, despite randomizing patients to treatment within 6 hours of entry to the intensive care unit. Possible reas<strong>on</strong>s for lack of success include failing to commence therapy within 6 hours of <strong>on</strong>set of injury and inadequate enrichment with AKI patients because of the brief profile of the specific pre-formed biomarker (a combinati<strong>on</strong> of gammaglutamyl transpeptidase and alkaline phosphatase). The trial will be used to highlight problems with current randomized c<strong>on</strong>trolled trial design and in particular to illustrate how biomarker performance varies with etiology of AKI, durati<strong>on</strong> of AKI, baseline GFR (before injury), severity and durati<strong>on</strong> of AKI and stage and phase of AKI. 75
E05 Liver and the Kidney 1: Principles of Hepatic Dysfuncti<strong>on</strong> Heather Patt<strong>on</strong> MD 4:00-5:30 Tuesday, February 14 Educati<strong>on</strong>al Objectives: 1. Understand the genesis of hyperdynamic circulati<strong>on</strong> that occurs with portal hypertensi<strong>on</strong> 2. Describe how renal resp<strong>on</strong>se to the hyperdynamic circulati<strong>on</strong> and relative cardiac dysfuncti<strong>on</strong> c<strong>on</strong>tribute to acute kidney injury in cirrhosis 3. Apply understanding of mechanisms of functi<strong>on</strong>al renal failure in end stage liver disease to current therapeutic strategies C<strong>on</strong>tent Descripti<strong>on</strong>: Hepatorenal syndrome (HRS), first described by Flint in 1963 (Am J Med Sci 1963;45:306-39), is a functi<strong>on</strong>al renal failure caused by severe intra-renal vasoc<strong>on</strong>stricti<strong>on</strong>. This occurs in the setting of circulatory dysfuncti<strong>on</strong> with increased plasma rennin activity, over-activity of the sympathetic nervous system, and increased anti-diuretic horm<strong>on</strong>e. The ability of the kidneys to excrete sodium and free water is severely diminished and presentati<strong>on</strong> with diluti<strong>on</strong>al hyp<strong>on</strong>atremia is comm<strong>on</strong>. Extra-renal arterial vasodilatati<strong>on</strong> occurs mainly in the splanchnic vascular bed, whereas other vascular beds, such as those that supply the brain and the liver, may be vasoc<strong>on</strong>stricted. These vascular derangements may c<strong>on</strong>tribute to the development of hepatic encephalopathy and decline in hepatocellular functi<strong>on</strong> observed in HRS. Cardiac output in HRS may be low, normal, or high but is insufficient because of reduced peripheral vascular resistance. The c<strong>on</strong>tributi<strong>on</strong> of diminished cardiac output to hepatorenal physiology is a more recent c<strong>on</strong>cept in this syndrome. It is hypothesized that a hyperdynamic circulati<strong>on</strong> is essential to maintenance of central blood volume and renal perfusi<strong>on</strong> in cirrhosis. When cardiac output decreases, effective hypovolemia occurs, leading to renal hypoperfusi<strong>on</strong> and HRS. The mechanism(s) leading to impaired or insufficient cardiac output in patients developing HRS is unknown. HRS can be triggered by a number of events including infecti<strong>on</strong>, bleeding, and large volume paracentesis (LVP) without administrati<strong>on</strong> of IV albumin. The most comm<strong>on</strong> trigger for HRS is bacterial infecti<strong>on</strong>, particularly sp<strong>on</strong>taneous bacterial perit<strong>on</strong>itis (SBP). Type-1 HRS occurs in about 25% of patients with SBP despite rapid resoluti<strong>on</strong> of the infecti<strong>on</strong> with administrati<strong>on</strong> of n<strong>on</strong>-nephrotoxic antibiotics. The annual incidence am<strong>on</strong>g patients with cirrhosis and ascites is estimated at 8% and is associated with poor prognosis. Patients with the rapidly progressive Type-1 HRS have a median survival of 2 weeks and a hospital survival of less than 10% whereas patients with the more insidious Type-2 HRS have a median survival of 6 m<strong>on</strong>ths. Kidney functi<strong>on</strong> can be improved with prompt medical treatment in patients with HRS and is associated with improved survival. Treatment of HRS is designed to increase the central blood volume by simultaneously increasing total plasma volume and reducing intense peripheral vasodilatati<strong>on</strong>. Suggested Reading: 1. Gines, P. and R.W. Schrier, Renal failure in cirrhosis. N Engl J Med, 2009. 361(13): p. 1279-90. 2. W<strong>on</strong>g, F., Nadim, M.K., Kellum, J.A., Salerno, F, Bellomo, R., Gerbes, A., Angeli, P, Moreau, R., Davenport, A., Jalan, R., R<strong>on</strong>co, C., Genyk, Y., and Arroyo, V. Working party proposal for a revised classificati<strong>on</strong> system of renal dysfuncti<strong>on</strong> in patients with cirrhosis. Gut 2011;60:702-709. 3. Jalan R, Forrest EH, Redhead DN, Dill<strong>on</strong> JF, Hayes PC. Reducti<strong>on</strong> in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man? Gut 1997;40(5):664- 70 4. Stadlbauer V, Wright GA, Banaji M, Mukhopadhya A, Mookerjee RP, Moore K, Jalan R. Relati<strong>on</strong>ship between activati<strong>on</strong> of the sympathetic nervous system and renal blood flow autoregulati<strong>on</strong> in cirrhosis. Gastroenterology 2008;134(1):111-9. 5. Helmy A, Jalan R, Newby DE, Hayes PC, Webb DJ. Role of angiotensin II in regulati<strong>on</strong> of basal and sympathetically stimulated vascular t<strong>on</strong>e in early and advanced cirrhosis. Gastroenterology. 2000;118(3):565-72 76
- Page 2 and 3:
CRRT 2012 SEVENTEENTH INTERNATIONAL
- Page 4 and 5:
FACULTY DISCLOSURES CRRT 2012 Facul
- Page 6 and 7:
CRRT 2012 ORGANIZING COMMITTEE USA
- Page 8 and 9:
CRRT 2012 FACULTY Patrick Honoré,
- Page 10 and 11:
ACKNOWLEDGEMENTS CRRT 2012 ACKNOWLE
- Page 12 and 13:
PLENARY SESSIONS CRRT 2012 PROGRAM/
- Page 14 and 15:
PLENARY SESSIONS CRRT 2012 PROGRAM/
- Page 16 and 17:
PLENARY SESSIONS CRRT 2012 PROGRAM/
- Page 18 and 19:
WORKSHOPS CRRT 2012 PROGRAM/INDEX T
- Page 20 and 21:
WORKSHOPS CRRT 2012 PROGRAM/INDEX W
- Page 22 and 23:
POSTER ABSTRACTS C
- Page 24 and 25:
POSTER ABSTRACTS C
- Page 26 and 27: NURSING FORUM LUNCHEON Communicatio
- Page 28 and 29: Nutritional Support in ICU Patients
- Page 30 and 31: Educational Objectives: The Endothe
- Page 32 and 33: SPECIAL LECTURE Engineering Critica
- Page 34 and 35: Nishimura R, Ornato JP, Page RL, Ri
- Page 36 and 37: Do Vasoactive Drugs and Fluids Impr
- Page 38 and 39: Blood Transfusions are Important fo
- Page 40 and 41: Thinking Outside of the Box: A Nove
- Page 42 and 43: Nursing Forum 2 Luncheon Benchmarki
- Page 44 and 45: 4. Mori K, Lee HT, Rapoport D, Drex
- Page 46 and 47: Differential Diagnosis of AKI: Can
- Page 48 and 49: Myocardial Stunning and Brain Edema
- Page 50 and 51: 4. Udy A, Roberts JA, Lipman J. Wha
- Page 52 and 53: CRRT and ECMO: Techniques and Outco
- Page 54 and 55: Management of Severe Heart Failure:
- Page 56 and 57: Avoiding Anticoagulation for CRRT:
- Page 58 and 59: Improving Outcomes from</st
- Page 60 and 61: The Changing Face of AKI: Snapshots
- Page 62 and 63: Alkaline Phosphatase Peter Pickkers
- Page 64 and 65: creatinine (Cr) was measured using
- Page 66 and 67: Surveillance and Early Recognition
- Page 68 and 69: therapy admitted to general intensi
- Page 70 and 71: A01 Assessing the Microcirculation
- Page 72 and 73: A01 Assessing the Microcirculation
- Page 74 and 75: C03 Critical Care Pharmacology: Vas
- Page 78 and 79: 6. Ferguson JW, Dover AR, Chia S, C
- Page 80 and 81: G07 Fluids and Solutions in the Cri
- Page 82 and 83: A09 Vascular Access /Membrane and C
- Page 84 and 85: A09 Vascular Access /Membrane and C
- Page 86 and 87: C11 Critical Care Management: Nutri
- Page 88 and 89: D12 Biomarkers 2: Application in AK
- Page 90 and 91: Educational Objectives: E13 Liver a
- Page 92 and 93: G15 Fluids and Solutions in the Cri
- Page 94 and 95: Educational Objectives: 1) Discuss
- Page 96 and 97: B18 Fluid Management Ravindra L. Me
- Page 98 and 99: C19 Acid Base and Electrolyte Probl
- Page 100 and 101: D20 Extracorporeal Techniques for S
- Page 102 and 103: the mediatordelivery hypothesis. In
- Page 104 and 105: F22 Ensuring Patient Safety and Qua
- Page 106 and 107: H24 Patient Centered Care in the IC
- Page 108 and 109: B26 Starting and Stopping RRT for A
- Page 110 and 111: C27 Acid Base and Electrolyte Probl
- Page 112 and 113: D28 Extracorporeal Techniques for S
- Page 114 and 115: E29 Heart Failure and Cardio-Renal
- Page 116 and 117: F30 Ensuring Patient Safety and Qua
- Page 118 and 119: H32 Withdrawing & Withholding Suppo
- Page 120 and 121: Patel SS, Holley JL. Withholding an
- Page 122 and 123: ABSTRACTS FROM 17
- Page 124 and 125: ABSTRACTS FROM 17
- Page 126 and 127:
ABSTRACTS FROM 17
- Page 128 and 129:
ABSTRACTS FROM 17
- Page 130 and 131:
ABSTRACTS FROM 17
- Page 132 and 133:
ABSTRACTS FROM 17
- Page 134 and 135:
ABSTRACTS FROM 17
- Page 136 and 137:
ABSTRACTS FROM 17
- Page 138 and 139:
ABSTRACTS FROM 17
- Page 140 and 141:
ABSTRACTS FROM 17
- Page 142 and 143:
ABSTRACTS FROM 17
- Page 144 and 145:
ABSTRACTS FROM 17
- Page 146 and 147:
ABSTRACTS FROM 17
- Page 148 and 149:
ABSTRACTS FROM 17
- Page 150 and 151:
ABSTRACTS FROM 17
- Page 152 and 153:
ABSTRACTS FROM 17
- Page 154 and 155:
ABSTRACTS FROM 17
- Page 156 and 157:
ABSTRACTS FROM 17
- Page 158 and 159:
ABSTRACTS FROM 17
- Page 160 and 161:
ABSTRACTS FROM 17
- Page 162 and 163:
ABSTRACTS FROM 17
- Page 164 and 165:
ABSTRACTS FROM 17
- Page 166 and 167:
ABSTRACTS FROM 17
- Page 168 and 169:
ABSTRACTS FROM 17
- Page 170 and 171:
ABSTRACTS FROM 17
- Page 172 and 173:
ABSTRACTS FROM 17
- Page 174 and 175:
ABSTRACTS FROM 17
- Page 176 and 177:
ABSTRACTS FROM 17
- Page 178 and 179:
ABSTRACTS FROM 17
- Page 180 and 181:
ABSTRACTS FROM 17
- Page 182 and 183:
ABSTRACTS FROM 17
- Page 184 and 185:
ABSTRACTS FROM 17
- Page 186 and 187:
ABSTRACTS FROM 17
- Page 188 and 189:
ABSTRACTS FROM 17
- Page 190 and 191:
ABSTRACTS FROM 17
- Page 192 and 193:
ABSTRACTS FROM 17
- Page 194 and 195:
ABSTRACTS FROM 17